Associated Papers
Ethnic differences in the metabolism, toxicology and efficacy of three anticancer drugs.
Sai K et al.
Expert Opinion on Drug Metabolism & Toxicology, 2011
Genetic polymorphism in metabolism and host defense enzymes: implications for human health risk assessment.
Ginsberg G et al.
Critical Reviews in Toxicology, 2010
[Pharmacogenomics for adverse drug reactions].
Saito Y et al.
Nihon Rinsho. Japanese Journal of Clinical Medicine, 2010
Uridine 5'-diphospho-glucuronosyltransferase genetic polymorphisms and response to cancer chemotherapy.
Ramírez J et al.
Future Oncology (london, England), 2010
Genetic polymorphisms in the tobacco smoke carcinogens detoxifying enzyme UGT1A7 and the risk of head and neck cancer.
Lacko M et al.
Head & Neck, 2009
Characterization of UGTs active against SAHA and association between SAHA glucuronidation activity phenotype with UGT genotype.
Balliet RM et al.
Cancer Research, 2009
Analysis of inherited genetic variations at the UGT1 locus in the French-Canadian population.
Ménard V et al.
Human Mutation, 2009
Family 1 uridine-5'-diphosphate glucuronosyltransferases (UGT1A): from Gilbert's syndrome to genetic organization and variability.
Strassburg CP et al.
Archives of Toxicology, 2008
Genetic variations and haplotypes of UDP-glucuronosyltransferase 1A locus in a Korean population.
Yea SS et al.
Therapeutic Drug Monitoring, 2008
Pharmacogenetics of uridine diphosphoglucuronosyltransferase (UGT) 1A family members and its role in patient response to irinotecan.
Nagar S et al.
Drug Metabolism Reviews, 2006
Haplotype structures of the UGT1A gene complex in a Japanese population.
Saeki M et al.
The Pharmacogenomics Journal, 0
Select a paper to view details